# Deborah Palestrant

> Deborah Palestrant is a seed investor at 5AM Ventures (Cambridge) backing Medical and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [5AM Ventures](https://shizune.co/investors/profile/5am-ventures)
- Location: Cambridge, United States
- Total investments: 3
- Last investment: Jul 2025
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/deborah-palestrant/2/570/125

Deborah Palestrant is a seed investor at 5AM Ventures in Cambridge focused on Medical and Health Care. Deborah Palestrant is Partner at 5AM Ventures. She attended D'Amore-McKim School of Business at Northeastern University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Renasant Bio | Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments. | $54.5M | Seed | Jul 10, 2025 |  |
| Latigo Biotherapeutics | Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability. | $150M | Series B | Mar 17, 2025 |  |
| Latigo Biotherapeutics | Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability. | $135M | Series A | Feb 14, 2024 |  |

3 of 3 investments shown.

## Co-investors
- [Westlake Village BioPartners](https://shizune.co/investors/profile/westlake-village-biopartners) — VC Fund, 4 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 3 deals together
- [Access Biotechnology](https://shizune.co/investors/profile/access-biotechnology) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together
- [Blue Owl](https://shizune.co/investors/profile/blue-owl-e2cf) — VC Fund, 1 deal together

## About 5AM Ventures

VC Fund · Menlo Park, United States

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

5 contacts available at 5AM Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Kush Parmar | Managing Partner | https://shizune.co/investors/profile/kush-parmar |
| Scott Rocklage | Founding Partner | https://shizune.co/investors/profile/scott-m-rocklage |
| Andrew Schwab | Managing Partner | https://shizune.co/investors/profile/andrew-schwab |
| Deborah Palestrant | Partner | https://shizune.co/investors/profile/deborah-palestrant |
| James W. Young | Venture Partner | https://shizune.co/investors/profile/james-w-young |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Deborah Palestrant invest in?

Deborah Palestrant invests primarily in Medical, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Deborah Palestrant last invest?

The most recent investment recorded for Deborah Palestrant closed in Jul 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co